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Abstract
A vascular component is increasingly recognized as important in Alzheimer's disease (AD). We
measured cerebral blood volume (CBV) in patients with probable AD or Mild Cognitive Impairment
(MCI) and in elderly non-demented subjects using a recently developed Vascular-Space-Occupancy
(VASO) MRI technique. While both gray and white matters were examined, significant CBV deficit
regions were primarily located in white matter, specifically in frontal and parietal lobes, in which
CBV was reduced by 20% in the AD/MCI group. The regions with CBV deficit also showed reduced
tissue structural integrity as indicated by increased apparent diffusion coefficients, whereas in regions
without CBV deficits no such correlation was found. Subjects with lower CBV tended to have more
white matter lesions in FLAIR MRI images and showed slower psychomotor speed. These data
suggest that the vascular contribution in AD is primarily localized to frontal/parietal white matter
and is associated with brain tissue integrity.
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1. Introduction
Alzheimer's disease (AD) is neurodegenerative disease associated with neuritic plaques
composed of beta amyloid and neurofibrillary tangles composed of hyperphosphorylated tau
protein. While amyloid/tau pathology is the primary focus in the field, recent evidence indicates
that vascular factors are important in the pathogenesis of AD (de la Torre, 2004). This evidence
comes from a wide spectrum of studies, including postmortem studies showing severe cerebral
angiopathy in AD patients (Chui et al., 2006; Jagust et al., 2008; Tian et al., 2006),
epidemiologic studies showing that many of the risk factors for AD are also associated with
vascular disease (hypertension, hypercholesterolemia, diabetes, and hyperhomocysteinemia)
(reviewed in de la Torre (2002)), and neuroimaging studies showing that AD patients have
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greater volume of white matter hyperintensities of possible ischemic origin (Delano-Wood et
al., 2008; Prins et al., 2004).
Brain vascular function can be assessed by several different methods. For in vivo studies,
cerebral blood flow (CBF), the amount of blood reaching the tissue per unit time (Kety and
Schmidt, 1948), is the most widely used parameter. Previous CBF studies in AD patients have
found pronounced blood flow deficits in temporoparietal cortex, posterior cingulate cortex,
and in some cases, frontal cortex (Alsop et al., 2000; Bartenstein et al., 1997; Ishii et al.,
1997; Johnson et al., 2005; Kogure et al., 2000). CBF is known to be coupled to metabolic
demand. Thus, although reduced CBF may be an indication of vascular dysfunction, it may
also be simply due to lower metabolic demand in these regions (de Leon et al., 2001; Reiman
et al., 2005; Small et al., 2000) in the face of relatively intact brain vasculature. In addition,
CBF is also governed by many factors external to the brain, such as cardiac output, autonomic
activity, and blood pressure. Therefore, it is necessary to study brain vasculature in AD with
alternative vascular parameters.
Cerebral Blood Volume (CBV), the amount of blood per 100 ml of brain parenchyma, is an
indicator of blood vessel lumen size and density. CBV has been less extensively studied than
CBF, but was recently shown to be useful in assessing neovascularization in brain tumors
(Law et al., 2004) and a good marker for angiogenesis and synaptogenesis (Pereira et al.,
2007; Swain et al., 2003). In addition, the sensitivity of CBV to physiologic variation is about
38% of that of CBF (Grubb et al., 1974). Thus, CBV may be less dependent on the subject's
depth and rate of respiration. We have recently developed a Vascular-Space-Occupancy
(VASO) Magnetic Resonance Imaging (MRI) technique to quantitate CBV (Lu et al., 2005).
In contrast with the Dynamic Susceptibility Contrast (DSC) MRI method, the VASO approach
is based on steady-state signal and does not depend on arterial input function, which itself may
be changed with disease. CBV measured by VASO shows a moderate correlation with that
using DSC MRI, but also displays some deviations (Lu et al., 2005), suggesting that the two
measures may have slightly different physiologic bases. The VASO technique also has the
advantage that the sensitivity is sufficient to assess vascular health in white matter, which is
ordinarily very difficult to assess due to very low vascularity.
In this study, we measured CBV in a group of patients with probable AD or Mild Cognitive
Impairment (MCI), and identified regions with significant CBV decline compared to elderly
non-demented controls. The relationship of CBV deficits to parenchymal damage was
examined by correlating the regional CBV values to tissue water diffusion index as measured
by diffusion tensor imaging (DTI), and the volume of white matter hyperintensities measured
by FLAIR MRI. In addition, the CBV result was compared to neuropsychological test scores.
2. Methods
2.1. Participants
A group of probable AD/MCI patients (n = 16, 9M, 7F, age (years ± S.D.) = 70.7 ± 9.3) and a
group of elderly controls (n = 10, 3M, 7F, age = 73.1 ± 4.4) were examined. The participants
were recruited from the longitudinal cohorts maintained by the Alzheimer's Disease Center of
University of Texas Southwestern Medical Center. The Health Insurance Portability and
Accountability Act (HIPAA) compliant protocol was proved by the Institutional Review Board
and written informed consent was obtained from all participants. Inclusion/exclusion criteria
for all subjects were: (a) No contraindication to MRI scanning (pacemaker, implanted metallic
objects, renal/liver disease), (b) general good health, with no serious or unstable medical
conditions, (c) able and willing to provide informed consent (in the case of AD/MCI patients,
caregivers co-signed consents), (d) age greater than 50, (e) no evidence of stroke in clinical
MRI, and (f) Hachinski et al. (1975) score < 4. Additional criteria for the control group were
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normal cognition and Clinical Dementia Rating (CDR; Morris, 1993) score = 0. Additional
criteria for the AD/MCI group included a diagnosis of probable AD based on NINCDS/
ADRDA criteria (McKhann et al., 1984) or a diagnosis of MCI based on Petersen criteria
(Petersen et al., 1997) with CDR score = 0.5–1. In this study, we grouped the probable AD (8
subjects, CDR = 1) and MCI (8 subjects, CDR = 0.5) patients together because of the evidence
that MCI is a potential pre-clinical form of AD (Petersen et al., 2001) and considerable overlap
between these two diagnostic entities. Special caution was used to exclude any subjects with
clinically obvious cerebrovacular disease (DeCarli et al., 2004), including a history of stroke,
focal neurologic findings, or MRI evidence of cerebral infarction. The demographic
information for the participants is summarized in Table 1.
2.2. MRI methods
The MRI investigatons were performed on a 3 T MR system (Philips Medical System, Best,
The Netherlands). A body coil was used for radiofrequency (RF) transmission and an 8-channel
head coil with parallel imaging capability was used for signal reception. We measured CBV
maps using the VASO MRI technique that was developed by our laboratory (Lu et al., 2003,
2005). For the VASO imaging protocol, we used 32 coronal slices (voxel size 2 mm × 2 mm
× 5 mm) to cover the entire brain. The other imaging parameters were: FOV = 192 mm × 192
mm, matrix size = 96 × 96, slice thickness = 5 mm, echo-planar-imaging (EPI) factor = 7, TR/
TE = 6000 ms/3.4 ms, duration = 2.5 min. The inversion time, TI, was selected to be 1088 ms
in accordance with the blood T1 estimate, 1624 ms (Lu et al., 2004). The scan protocol included
a pre-contrast scan, injection of contrast agent by an MRI Power Injector (MEDRAD,
Pittsburgh, PA) and a post-contrast scan. An FDA-approved contrast agent, Gd-DTPA
(Magnevist®), was used with a standard dosage (0.1 mmol/kg). The post-contrast VASO scan
was initiated 2 min after the injection to avoid signal fluctuations due to bolus passes.
In addition to the CBV images, a T1-weighted high resolution (1 mm × 1 mm × 1 mm)
anatomical image using a magnetization-prepared rapid acquisition of gradient echo
(MPRAGE) sequence (Brant-Zawadzki et al., 1992) was acquired for each subject for the use
of brain normalization. We also acquired Diffusion Tensor Imaging (DTI) (TR/TE = 5281 ms/
51 ms, FOV = 224 mm × 224 mm, resolution = 2 mm × 2 mm, 60 slices with thickness = 2
mm and gap = 1 mm) and Fluid-Attenuated Inversion Recovery (FLAIR) images (Essig et al.,
1998) (TR/TI/TE = 11000 ms/2800 ms/ 125 ms, FOV = 230 mm × 230 mm, resolution = 0.45
mm × 0.45 mm, 24 slices with thickness = 5 mm and gap = 1 mm) for assessment of structural
changes. The FLAIR scan was performed on 24 participants and all data were included in the
analysis. The DTI scan was performed on 26 participants, but one subject showed significant
motion artifact and was omitted from analysis. The DTI scan uses a single-shot spin echo EPI,
and the diffusion encoding gradients have 30 directions based on the optimal scheme of Jones
et al. (1999) with a b-factor of 1000 s/mm2. The total scan duration was approximately 32 min.
Psychological testing results, including Mini-Mental State Exam (MMSE) (Folstein et al.,
1975), Trail-making Tests A and B (Reitan, 1955), and the Consortium to Establish a Registry
for Alzheimer's Disease (CERAD) battery (Morris et al., 1989), were available for comparison
with the MRI data.
2.3. Data processing
Magnitude and phase MR images of the VASO scans were reconstructed on the scanner. The
phase image was used to determine the sign of the magnetizations. The sign-corrected pre- and
post-contrast VASO images were co-registered by Statistical Parametric Mapping (SPM2) and
the CBV was calculated using an algorithm described previously (Lu et al., 2005):
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where Spre and Spost are the MRI signals before and after the contrast agent injection,
respectively, M0 the MRI signal for a pure-water voxel at equilibrium magnetization, Cb is the
water content of blood and is assumed to 0.87 ml water/ml blood (Herscovitch and Raichle,
1985). The M0 for each subject is estimated from a proton-density weighted images (TR =
20000 ms, TE = 10 ms).
To spatially register the individual CBV maps into a standard brain template so that group
comparison can be performed, we used the following steps (Fig. 1) to obtain a “normalized
CBV” for each subject. The raw CBV map was co-registered (rigid-body registration) by SPM2
to the subject's T1-weighted anatomical image. The individual T1-weighted image was then
registered (elastic registration) to a template T1 image. This step used an elastic registration
algorithm, Hierarchical Attribute Matching Mechanism for Elastic Registration (HAMMER)
proposed by Shen and Davatzikos (2002), which detects and corrects for region-specific brain
atrophy (Davatzikos et al., 2001). This feature is important to ensure that the comparison truly
reflects vascular parameters rather than brain volume reduction. Once the individual T1 image
was registered to the template brain, the same geometric transformation was applied to the
individual CBV map so that the CBV map is now also in the standard space. Finally, in order
to remove the effect of global CBV variations across subjects and focus on regional differences
between AD/MCI subjects and controls, we divided the CBV value of each voxel by the mean
CBV value of the cerebellum. Cerebellum was chosen as the reference tissue because
cerebellum is minimally affected in AD (Karbe et al., 1994).
For voxel-by-voxel analysis, the normalized CBV map was smoothed by a Gaussian filter with
12 mm full-width-at-half-maximum (FWHM) (Alsop et al., 2000; Ashburner and Friston,
2000; Johnson et al., 2005).We conducted a two sample t-test using SPM2 to identify clusters
showing significant CBV deficit (p < 0.005, voxel cluster size > 1250 mm3) (Xu et al.,
2007). We also performed a manual region-of-interest (ROI) analysis based on the normalized
images. The regions examined included frontal white matter, parietal white matter, occipital
white matter, hippocampus, and parietotemporal gray matter. Circular ROIs of 6-mm (for
parietotemporal gray matter) or 8-mm (for other regions) diameter were carefully positioned
in different anatomic regions to calculate the regional CBV values. In addition, similar ROI
analysis was performed on the individual images to test the reliability of the results.
Apparent diffusion coefficient (ADC) and fractional anisotropy (FA) were calculated from the
DTI images using DTI studio (Johns Hopkins University, Baltimore, MD). ADC and FA maps
were then normalized to the template space in the same way as described for the CBV maps.
The hyperintensity voxels in FLAIR images were identified with a semi-automatic method
(Marquez de la Plata et al., 2007). Briefly, the FLAIR images were skull-stripped and the voxels
with signal intensity greater than 2 standard deviations above average were delineated as a
preliminary mask. Next, the preliminary mask was manually edited to remove spurious voxels
due to fat signal, motion effect, edge effect, or coil sensitivity inhomogeneity. The total volume
within the final mask was quantified for each subject. For correlation analysis between CBV,
diffusion parameters, and neuropsychological test scores, the CBV deficit clusters as defined
from the voxel-based comparison were used as masks for spatial averaging. Pearson correlation
coefficients were calculated to assess the significance of the correlation. We also calculated
Spearman rank correlation to assess the possible influence of outlier points.
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Fig. 2a and b shows the averaged CBV maps of the AD/MCI and control groups, respectively.
Fig. 3 shows a voxel-by-voxel group comparison. After applying statistical threshold (p < 0.005
for each voxel, cluster size > 1250 mm3), the regions showing CBV decline were overlaid on
the T1 weighted anatomic image. Significant CBV deficits were observed primarily in white
matter, located bilaterally in frontal lobes and extending to parietal lobes (Fig. 3). No significant
clusters were observed for the opposite contrast (i.e., CBV in AD/MCI group greater than CBV
in controls). The voxel-based results are consistent with the manual ROI results, which showed
that CBV in AD/MCI patients were 26.1% (p < 0.001) and 18.5% (p = 0.015) lower than in
controls in frontal and parietal white matters, respectively (Fig. 4). This trend was also seen in
occipital white matter, but the level of statistical significance was lower (p = 0.04). No
significant difference was observed in parietotemporal gray matter and hippocampus. The ROI
analysis performed on the individual images showed the similar results: The AD/MCI patients
showed significant CBV deficit in the three white matter ROIs while no significant difference
was observed in parietotemporal gray matter and hippocampus.
To assess the effect of CBV deficit on neural tissue integrity, diffusion parameters in regions
showing CBV deficits were calculated. Fig. 5 shows a significant negative correlation (Pearson
correlation p = 0.021, r = 0.41; Spearman rank correlation p = 0.027, r = 0.39) between apparent
diffusion coefficient (ADC) and the CBV values across subjects, suggesting that subjects with
lower CBV had higher diffusion coefficients. A higher ADC indicates that water molecules
diffuse more freely, implying reduced tissue structural barrier due to axonal membrane and
myelin damage. In order to further confirm that the observed ADC change is related to CBV
decline and not a global phenomenon, we performed additional analysis in which another set
of white matter voxels (with the same number of voxels) were selected based on the criterion
of similar CBV between AD/MCI and controls (i.e., t-test statistic around 0). In these voxels,
no correlation was found between CBV and ADC across subjects (Pearson correlation p = 0.37,
r = 0.07; Spearman rank correlation p = 0.28, r = 0.12). We also performed correlation analysis
between CBV and fractional anisotropy (FA), but did not find a significant correlation (Pearson
correlation p = 0.46, r = 0.02; Spearman rank correlation p = 0.36, r = 0.07), suggesting that
vascular insult to white matter can change the tissue diffusion coefficient but this change
appears to be present in all directions (both parallel and perpendicular to the axon tracts).
Volume of white matter hyperintensities (WMH) on FLAIR image is another index of tissue
damage. Fig. 6 plots the correlation between CBV and WMH volume. A weak correlation
(Pearson correlation p = 0.101, r = 0.27; Spearman rank correlation p = 0.049, r = 0.35) can
be seen, suggesting that subjects with lower CBV tend to have a greater volume of WMH. This
relationship, however, barely reached statistical threshold and the data showed large dispersion.
One possible reason is that WMH are also produced by non-vascular causes of
neurodegeneration and inflammation (Kates et al., 1996).
We also examined the correlation between CBV and several neuropsychological tests including
MMSE, Trail-making Tests A and B, and the CERAD battery. We found that the normalized
CBV values correlated with impairment of performance on the Trails A test (Pearson
correlation p = 0.051, r = 0.34; Spearman rank correlation p = 0.094, r = 0.27). The other tests
also showed a trend of correlation (lower CBV corresponding to poor performance), but did
not reach significance.
4. Discussion
We compared CBV in a group of patients with probable AD or MCI with CBV in an elderly
control group. We found that CBV in these patients declines in frontal and parietal lobes;
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primarily in white matter. The CBV changes are correlated with structural damage as measured
by diffusion tensor imaging, which appears to be specific to CBV deficit regions and was not
found in regions where CBV was normal. The structural consequences of the CBV deficit are
further confirmed by WMH volume, which increased with lower CBV values. Finally, the
lower CBV and the structural damage were associated with reduction of psychomotor speed.
The CBV deficit regions identified by this study suggest that frontal white matter is probably
the most vulnerable tissue in terms of vascular contributions to AD and is consistent with the
observation that cerebrovascular pathology affects frontal lobe functions (Nagata et al.,
2000; Reed et al., 2000). In this regard, it is possible that the CBV deficit investigated in this
study indicates the vascular contribution to the dementia of AD. Thus, it is likely that many
AD patients have combined neurodegenerative and vascular pathology underlying the clinical
manifestations of the disease. Given the common co-existence of these two components in the
majority of patients, the characterization of vascular factor is important. The observation that
CBV deficit regions are mainly in white matter may be associated with autoregulation
differences between gray and white matter. Cerebral autoregulation is characterized by the
response that, when perfusion pressure is low, the blood vessels (primarily arterioles and small
arteries) can actively dilate to “attract” more blood to the tissue. Since gray matter has greater
vascularities, it is likely to have higher autoregulatory capacity. The white matter, on the other
hand, only has about 1/3 of the blood vessels, therefore may deplete its autoregulatory capacity
before gray matter.
Recent studies support that vascular dysfunction in frontal lobe is of significant relevance in
the pathogenesis of AD. Nishimura et al. (2007) performed a longitudinal study in which
perfusion deficits in frontal and temporoparietal lobes were measured and the disease
progression was monitored using serial MMSE scores. They found that frontal lobe deficit (at
baseline) was more predictive of future cognitive decline than were temporoparietal regions.
Another recent study on transgenic mouse models (Meyer et al., 2008) has reported that
vascular alteration in AD is not simply a generalized reduction of vascular density, but instead
involves significant uneven redistribution/remodeling of vascular networks. This can
potentially decouple CBV and CBF. The authors have further mapped the spatial specificity
of the vascular abnormalities and noted that the deficits prominently clustered in the frontal
cortex as well as temporal cortices.
Many previous studies have examined CBF deficit in AD and identified temporoparietal cortex
and posterior cingulate cortex as the primary affected regions in AD (Alsop et al., 2000;
Bartenstein et al., 1997; Ishii et al., 1997; Johnson et al., 2005; Kogure et al., 2000), differing
from findings in the present study. One possible reason for the discrepancy is that CBF can be
affected by other factors such as metabolic demand. This notion is supported by the
observations that the CBF deficit regions, e.g. posterior cingulate cortex, hippocampus, also
show a deficit in glucose metabolism as measured by FDG-PET (Mosconi et al., 2005;
Perneczky et al., 2007). Thus, CBF reduction may not be due to brain vascular dysfunction,
but could be related solely to lower metabolic demand/neural activity. Another possible reason
is that the AD/MCI group recruited for this study is at an early stage (mean MMSE = 26.6)
while those of the studies reporting significant CBF deficit are at a later stage. For example,
Alsop et al. (2000) used AD subjects with a mean MMSE score of 20.8. In a study that examined
similar stage of patients (mean MMSE = 27.7) (Johnson et al., 2005), no significant CBF deficit
in white matter was found, but in our study, an MR contrast agent was used to enhance the
sensitivity, which might have allowed the detection of deficit in white matter. A few previous
studies have also examined vascular dysfunction in AD using CBV measures derived from
DSC MRI (Bozzao et al., 2001; Gonzalez et al., 1995; Harris et al., 1998; Maas et al., 1997).
Although a moderate CBV deficit was noted in temporoparietal cortex when using a relatively
low threshold of p < 0.05 (Harris et al., 1998), these studies did not correct for regional atrophy
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during the CBV comparison. In view of pronounced temporal lobe atrophy commonly observed
in AD patients (Thompson et al., 2003), the CBV differences may be, at least partly, attributed
to the tissue volume loss, as also noted by the authors (Harris et al., 1998). A second possible
reason is that the CBV measures derived from DSC MRI may actually contain some
contributions from CBF, due to the use of arterial input function in the DSC data processing
(Ostergaard et al., 1996).
We have also specifically examined the CBV values in medial temporal lobe (MTL), the
primary site of brain atrophy and amyloid plaque deposition, using both voxel-based analysis
and ROI-based analysis. We did not observe a CBV decrease or a trend of decrease in MTL,
indicating that vascular insult is not a major factor in this region for the subjects recruited for
this study. This result supports the notion that MTL pathology in AD is not vascular in origin.
Furthermore, given the repeated observation that plaque and tangle accumulation begins in
MTL and only later affects parietal lobe and frontal lobes (Thompson et al., 2003), our
observation of frontal lobe-dominant CBV deficit in AD/MCI patients suggests that the
neurodegenerative and vascular pathologies in AD may be two separate processes. However,
it should be noted that a recent in vivo mapping of amyloid deposition has shown greater
deposition in frontal lobe than in the MTL (Buckner et al., 2005).
We were surprised that lower scores on Trails A, an assessment of psychomotor speed, showed
correlation with our measures of vascular dysfunction while the tests more sensitive to
cognitive impairment (Trails B and the CERAD Battery) did not. However, given our finding
of predominantly white-matter-specific CBV deficits, this result is consistent with the notion
that white matter integrity is critical for the speed of neuronal transmission. On the other hand,
cognitively demanding tasks such as Trails B and CERAD require more gray matter processing
and gray matter has more CBV reserve. Thus the correlations between these tasks and the CBV
measures were not strong.
5. Conclusion
Vascular factors may contribute to the pathogenesis of AD. While both gray and white matter
were examined, significant CBV deficit regions were primarily located in the white matter of
the frontal and parietal lobes, in which CBV was reduced by ∼20% in the patient group. These
CBV deficits correlated with parenchymal damage as assessed by diffusion tensor imaging and
FLAIR MRI. In addition, the amount of CBV deficit also appeared to correlate with impairment
of psychomotor speed.
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Procedure for the calculation of normalized CBV. The signal differences between pre- and
post-contrast VASO images were first calculated, which was realigned to the T1-weighted
anatomic image. The image of each individual was then registered to the brain template using
an elastic transformation. The CBV value of each voxel was normalized to the cerebellum CBV
to reduce the effect of normal variations in global CBV.
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Group averaged CBV maps in AD/MCI and control subjects. (a) Relative CBV maps in AD/
MCI patients. (b) Relative CBV maps in controls. The scale of the color bar is from 0 to 2.5
times the cerebellum CBV. (c) An anatomical image corresponding to the slices presented. (d)
The locations of coronal slices are marked in a sagittal anatomical image. (For interpretation
of the references to color in this figure legend, the reader is referred to the web version of the
article.)
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Results of voxel-based analysis with two sample t-test on the CBV maps of AD/MCI and
control groups. The colored regions show significant CBV deficit in AD/MCI patients (p <
0.005 and minimum cluster size = 1250 mm3). The color bar indicates Student's t-statistic
value. (For interpretation of the references to color in this figure legend, the reader is referred
to the web version of the article.)
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ROI analysis results of CBV in AD/MCI and control groups. 8-mm (frontal, parietal, and
occipital WM, hippocampus) or 6-mm (parietotemporal GM) diameter circles were drawn on
each subject's normalized CBV maps to obtain the mean value for each ROI. The asterisks
indicate regions with significant differences (two sample Student's t-test, p < 0.05).
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Correlation between CBV and ADC values across subjects (including both AD/MCI patients
and controls, n = 25). The values of CBV and ADC for each subject were calculated from the
regions showing significant CBV deficits (see Fig. 3).
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Correlation between the normalized CBV and the volume of white matter lesion measured by
FLAIR images (including both AD/MCI patients and controls, n = 24). The value of CBV for
each subject was calculated from the regions showing significant CBV deficits, and the volume
of white matter lesion was from the entire brain.
Uh et al. Page 16

























Uh et al. Page 17
Table 1
Demographic information of the participants.
Characteristic Control group AD/MCI group
Number of subjects 10 16
Mean age ± S.D. 73.1 ± 4.4 70.7 ± 9.3
Gender
 Male 3 9
 Female 7 7
Education (years) ± S.D. 14.8 ± 2.6 14.8 ± 3.2
MMSE score ± S.D. 28.7± 1.9 26.6 ± 3.5
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